<!DOCTYPE html>
<html>
<head>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="stylesheet" href="https://iannouvel.github.io/clerky/styles.css">
</head>
<body>
    <h1 style="font-weight: bold; text-decoration: underline;">Atypical Hyperplasia</h1>
    <p><strong>Source:</strong> GTG 67</p>
    <p><strong>Summary:</strong></p>
    <ul>
        <li>Risk of progression ~ 40%</li>
        <li>If declines surgery:
            <ul>
                <li>Explain risks</li>
                <li>Consider imaging to rule out invasive Ca, discuss with MDT</li>
                <li>Advise IUS, 2nd line continuous oral progestogens</li>
                <li>3-monthly endometrial surveillance until 2 consecutive negative samples</li>
                <li>Histological disease regression = 2 consecutive negative samples</li>
                <li>If has histological disease regression, long-term follow-up is 6-12 month biopsy until hysterectomy</li>
                <li>If desires fertility, advise at least 1 negative sample prior to conception AND refer to fertility</li>
            </ul>
        </li>
    </ul>
    <h2 style="font-weight: bold;">Major Risk Factors</h2>
    <ul>
        <li>Oestrogen (HRT)</li>
        <li>Tamoxifen</li>
        <li>PCOS</li>
        <li>Obesity</li>
        <li>Immunosuppression (transplant)</li>
    </ul>
    <h2 style="font-weight: bold;">Atypical Hyperplasia Key Points</h2>
    <ul>
        <li>Total hysterectomy indicated as risk of underlying malignancy or progression to cancer (studies show progression rates are 30-50%)</li>
        <li>IUS or oral progesterones alternatives for women who decline surgery</li>
    </ul>
</body>
</html>
